Evotec and UCB continue hunt for immunology targets
Hamburg/Brussels - Evotec AG and UCB Pharma seem to be satisfied with their relationship. The Belgian pharmaceutical company entered into a second multi-year, multi-target integrated drug discovery collaboration with Evotec in the field of immunology. This was announced by Evotec on Wednesday. As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules against a selected number of targets. The molecules will be further optimised and progressed through lead optimisation to a pre-clinical candidate. "Evotec is the ideal partner to provide the resource bandwidth and drug-hunting expertise to complement our internal efforts to progress this strategically important programme", commented Smail Kola, UCB NewMedicines' president. Besides a basic fee, Evotec will receive payments for early stage discovery, preclinical and clinical milestones. In addition Evotec will receive royalties based on net sales of any approved drugs from the collaboration.